

# Fusion Pharmaceuticals To Present At Upcoming September Investor Conferences

HAMILTON, ON and BOSTON, Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences.

- The H.C. Wainwright 25th Annual Global Investment Conference – The Company presentation will take place on Tuesday, September 12, 2023 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Financial Officer John Crowley.
- The Morgan Stanley 21st Annual Global Healthcare Conference – The fireside chat will take place on Wednesday, September 13, 2023 at 3:35 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at <https://ir.fusionpharma.com/events-webcasts>. A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.

## About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRIs) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical.

## Contact:

Amanda Cray  
Senior Director of Investor Relations & Corporate Communications  
(617) 967-0207  
[cray@fusionpharma.com](mailto:cray@fusionpharma.com)

SOURCE Fusion Pharmaceuticals

---

<https://ir.fusionpharma.com/2023-09-05-Fusion-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences>